Skip to content

Human immune cell-derived iPS cells to establish treatment model of human diseases

Human immune cell-derived iPS cells to establish treatment model of human diseases - Generation of Disease Treatment Model with iPS cells

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000040927
Enrollment
20
Registered
2020-06-29
Start date
2017-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Interventions

None listed

Sponsors

Chiba University
Lead Sponsor
RIKEN Center for Integrative Medical Sciences
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age : Between 20 and 59 years old. 2) Those who agree to take a medical consultation by a doctor 3) Those who agree to take blood tests, including tests on infectious diseases, twice: the second blood test will be conducted after a window period 4) Systolic blood pressure must be between 90 and 160 mmHg, and diastolic blood pressure must be 100 mmHg and less 5) Weight : Male 45kg and above; Female 40kg and above 6) Those who acknowledge to understand the terms and conditions of this study, and sign study participant agreement of their own free will, after receiving sufficient explanation on participation in this study.

Exclusion criteria

Exclusion criteria: In accordance with the Biological Raw Materials Standards, we exclude subjects who fall into either of the following categories based on medical consultations and/or tests: 1) Those who have a diseases that requires tretments or medications, or is being tested for a suspected disease. 2) Those who have a history of the second degree Vasovagal Reaction and more 3) Those who have a history of the following diseases: ? Malignant diseases ? Respiratory diseases (except transient inflammation, and bronchial asthma more than 1 year after cure) ? Cardiovascular diseases (except cases of congenital heart diseases with no symptoms, untreated, and no screening-detected abnormal ECG) ? Inflammatory bowel diseases ? Endocrine diseases (except diabetes which are well controlled only by diet therapy) ? Renal diseases (except acute nephritis which have been cured) ? Collagen diseases, and autoimmune diseases ? Cerebrovascular disorders, and epilepsy ? Hepatitis (except hepatitis A or D more than 6 months after being cured) 4) Those who have been diagnosed with a genetic disorder or who have a family history of a genetic disorder 5) Those who have received a blood transfusion or an organ transplant, or who have undergone organ donation 6) Those who are currently pregnant, or within 1 year after giving birth 7) Those who have been diagnosed with or are suspected to have transmissible spongiform encephalopathy, dementia, or mental illnesses. 8) Those who have a history of the following infectious diseases: ? Malaria, Chagas disease, or Toxoplasma gondii infection ? Tuberculosis within 5 years after being cured ? Sexually Transmitted Diseases within 1 year after being cured ? Dengue fever within 1 month after being cured ? Erythema infectiosum within 6 months after being cured, or an onset of eryhema infectiosum among family members within 1 month 9) Those whose primary doctor consider inappropriate to participate in this study

Design outcomes

Primary

MeasureTime frame
number of established master cell banks

Countries

Japan

Contacts

Public ContactShinichiro Motohashi

Graduate school of Medicine, Chiba University Department of Medical Immunology

motohashi@faculty.chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026